Founded
31 Dec 2005
Address
BioRelix Inc
5 Science Park
401 Winchester Avenue
New Haven, CT 06511
United States
Biorelix Inc
5 Science Park
401 Winchester Avenue
New Haven, CT 06511
United States
Biorelix Inc
5 Science Park
401 Winchester Avenue
New Haven, CT 06511
United States
Biorelix Inc
5 Science Park
401 Winchester Avenue
New Haven, CT 06511
United States
Biorelix Inc
5 Science Park
401 Winchester Avenue
New Haven, CT 06511
United States
Website
VCID: 452786
Profile
Corporate information
Official name
BioRelix Inc
Registration country
Official name
BioRelix Inc
Registration country
Investment activity status
Active investor
Company type
Advanced fight against drug resistant microbes by attacking novel targets with novel drugs.Funding
Funding rounds
N/A USD 269,000
USD 269,000 (1 Apr 2012)
| Investor | Profile | Country | Notes | |
|---|---|---|---|---|
|
Connecticut Innovations Inc | United States | Led the round. |
N/A USD 2,560,000
USD 2,560,000 (22 Mar 2012)
| Investor | Profile | Country | Notes | |
|---|---|---|---|---|
![[node:title] photo](/sites/default/files/styles/icon/public/default_images/icon-person.png?itok=8SSzz6Wf "[node:title] photo"){kind=icon}
|
Brian Dixon | |||
|
OpGen Inc | Provider of Whole Genome Mapping technologies for high-precision microbial analysis markets. | United States | |
|
New Leaf Venture Partners | United States | Follow-on investment. | |
|
Novartis Venture Funds | The corporate venturing arm of Novartis. | Switzerland | Follow-on investment. |
Series A USD 25,750,000
USD 25,750,000 (4 Jun 2007)
| Investor | Profile | Country | Notes | |
|---|---|---|---|---|
|
CHL Medical Partners | Venture capital firm focused on early-stage healthcare sectors. | United States | Follow-on investment. Led the round. Ronald W Lennox |
|
Aisling Capital | United States | Initial investment. Round participant. | |
|
|
New Leaf Venture Partners | United States | Initial investment. Round participant. | |
|
|
Alexandria Real Estate Equities Inc | United States | Follow-on investment. Round participant. | |
|
|
Elm Street Ventures | United States | Follow-on investment. Round participant. | |
|
|
Novartis Venture Funds | The corporate venturing arm of Novartis. | Switzerland | Follow-on investment. Round participant. |
| Investor | Profile | Country | Notes | |
|---|---|---|---|---|
|
|
Alexandria Real Estate Equities Inc | United States | Initial investment. | |
|
|
CHL Medical Partners | Venture capital firm focused on early-stage healthcare sectors. | United States | Initial investment. |
|
|
Elm Street Ventures | United States | Initial investment. | |
|
|
Novartis Venture Funds | The corporate venturing arm of Novartis. | Switzerland | Initial investment. |
Cap Table
Current and past shareholders
| Investor | Contacts | Round | |
|---|---|---|---|
|
|
Aisling Capital |
+1 (212) 651-6380 |
Series A |
|
|
Alexandria Real Estate Equities Inc |
+1 (626) 578-0777 |
Seed Series A |
|
|
Brian Dixon |
N/A | |
|
|
CHL Medical Partners Venture capital firm focused on early-stage healthcare sectors. |
+1 (203) 324-7700 |
Seed Series A |
|
|
Connecticut Innovations Inc |
+1 (860) 563-5851 |
N/A |
|
|
Elm Street Ventures |
+1 (203) 401-4201 |
Seed Series A |
|
|
New Leaf Venture Partners |
+1 (646) 871-6400 |
N/A Series A |
|
|
Novartis Venture Funds The corporate venturing arm of Novartis. |
+41 (61) 324-6210 |
N/A Seed Series A |
|
|
OpGen Inc Provider of Whole Genome Mapping technologies for high-precision microbial analysis markets. |
N/A |